Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis

Lupus Nephritis Clinical Trial

Official title:

Long-term Follow-up for Safety Evaluation of Subjects Who Participated in the Phase 1 Clinical Trial of CS20AT04(CS20AT04-LN101) in Lupus Nephritis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04522505
• Other study ID #: CS20AT04-LN101-E
• Status: Active, not recruiting
• Start date: November 29, 2017
• Est. completion date: May 24, 2024

Study information

• Verified date: February 2024
• Source: Corestemchemon, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This observation study is planned to evaluate the safety and efficacy of the subjects who received CS20AT04 in the phase 1 clinical trial.

If the subjects who participated in the phase 1 clinical trial voluntarily agree to participate in this observation study, visit 1 and visit 2 will be conducted every 3 months according to the clinical trial protocol until 6 months after administration of CS20AT04 in the phase 1 clinical trial. And Visit 3 after 6 months, Visit 4~Visit 7 will be conducted every 12 months. During each visit, subjects are assessed for the efficacy and occurrence of adverse events.

Description:

Lupus is a representative autoimmune disease that affects the whole body. It is occurred by generation of autoantibody and immune complex due to abnormal activation of the immune cells on the basis of abnormal immune responses.

Although about 50% of lupus patients have lupus nephritis, there is no therapeutic product targeting for the lupus nephritis so far.

The investigator has performed the pre-clinical and clinical studies using allogenic bone marrow derived mesenchymal stem cells in SLE.

CS20AT04 has anti-inflammatory effects, controls activity of immune cells and reduces generation of autoantibodies. So, it is expected to have therapeutic effects on lupus nephritis.

Phase 1 clinical trial was conducted as a single center, open-label.

The main component of CS20AT04 is bone marrow-derived mesenchymal stem cells. And the risk of tumor formation is low. Through the repeated administration and long-term observation with mouse model, it was confirmed that there was no oncogenicity. In addition, it was confirmed through the cell residual tracking test of the animal model that the in vivo residual period was shorter than 14 days.

However, since long-term safety has not been evaluated after administering CS20AT04 to humans, the investigator will confirm the safety of stem cells for up to 5 years according to the risk management plan for stem cell products of the Ministry of Food and Drug Safety and already approved phase 1 clinical trial.

Also In the phase 1 clinical trial that only confirmed safety and tolerability for 28 days after administration of CS20AT04, it is difficult to confirm the continuous change of the indicator for evaluating efficacy.

So, it is necessary to check the efficacy in this observation study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 7
• Est. completion date: May 24, 2024
• Est. primary completion date: February 7, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 17 Years to 70 Years

Eligibility

Inclusion Criteria:

• A Person who enrolled in a phase 1 clinical trial using CS20AT04 (CS20AT04-LN101) and administered CS20AT04 and has been 3 months.

• A person who voluntarily consent to participate in this observational study

*Phase I clinical trial Inclusion Criteria

• Patients with HLA-haplo-matched bone marrow donor is less than 70 years old.

• Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.

• Patients had suffered from active renal disease in the past or patients has active renal disease now. Active renal disese should have include below.

Spot urine protein/creatinine ratio = 1.0 and ? >5 RBC/HPF, ? >5 WBC/HPF, ? columnar cell.

Biopsy confirmed active type III or type IV, or type V lupus nephritis. Patients can be immunosuppressive agent to , steroids, taking, such as anti-Malarials (hydroxychloroquine) in a certain capacity, during the test period, to maintain the same capacity before 4-weeks screening.

Patients who consented to participate in the study in writing by themselves or their legal representatives.

Exclusion Criteria:

• A person who do not agree to participate in this follow up observational study among the subjects enrolled in a phase 1 clinical trial using CS20AT04.

*Phase I clinical trial exclusion criteria

• Those who do not kidney disease for SLE.

• Patients with a history of hypersensitivity, such as heavy metal poisoning similar to drug testing and drug ingredients.

• Patients a history Major organs (kidney, liver, lung, heart) transplant or liver hematopoietic cells / transplant or during of scheduled transplantation clinical trial.

• patients a history of kidney dialysis or during of the scheduled dialysis clinical trials within 2 weeks prior to the screening.

• Tested positive for hepatitis B(HBsAg, Anti-HBcAB, HBV-DNA) and hepatitis C(Anti-HCV, HCV-RNA).

• Patients a history of anaphylactic reaction for the parenteral administration of a monoclonal antibody or contrast agent, a mouse protein or human.

• Patients whose e-GFR = 30mL/min at screening.

• Patients with a history of malignancy within 5 years prior to the screening(basal cell carcinoma of skin, squamous cell carcinoma of skin, or cervical intraepithelial neoplasia are excluded).

• Patients who were administered drug of the follow within 6 months prior to the screening.

nitrogen mustard, chlorambucil, vin·cris·tine, procarbazine, Abatacept, Rituximab, Belimumab Patients who were administered drug of the follow within 3 months prior to the screening.

Anti-TNF therapy(Etanercept, adalimumab, Infliximab, golimumab, Tocilizumab) Interleukin-1 receptor antagonist(anakinra) Intravenous immunoglobulin(IVIG) Plasmapheresis

• Those who are hypersensitive to antibiotics including penicillin and streptomycin.

• Patients with systemic infection at screening.

• Uncontrolled hypertension or diabetes.

• If that may affect proteinuria increased capacity or begin taking medication(ACE inhibitors, ARB (Angiotensin Receptor Blocker)) (However, more than four weeks allowed capacity, taking is possible during the trial period without changing capacity).

• Patients who showed myocardial infarction or angina on ECG at screening, or received stent procedure or bypass.

• Patients who were administered another study drug 3 months prior to the study.

• Patients with severe mental disease(for example, schizophrenia, bipolar disorder etc;).

• Patients are expected to be administered the combination contraindicated drugs about inevitable or taker within clinical trial.

• Women of childbearing age are not implement adequate contraception during clinical trials. the proper method of contraception, which has Oral contraceptive continued more than four weeks, a surgical procedures including the insertion loop, condom use etc. and Medically it is determined that there is no possibility of pregnant women do not belong to women of childbearing age due to the ovary removal, hysterectomy and menopause, etc.

• Pregnant women or nursing women.

• Except as permitted in the following Case and laboratory test results than moderate adverse events(NCI-CTC (National Cancer Institute-Common Toxicity Criteria) version 4.0) grade 3.

• Class III due to stable prothrombin time of warfarin therapy

• Lupus anticoagulant group, and are not associated with liver disease or stable anticoagulation 3 grade partial thromboplastin time

• Lupus due to hepatitis and alcoholic liver disease, are not associated with uncontrolled diabetes or viral hepatitis stable 3 grade gamma glutamyl transferase (GGT) increases. If it appears to be less than ALT and / or AST is above all on the second level.

• Stable grade 3 neutropenia or white blood cell count

• Patients who previously received stem cell therapy.

• Subjects who by the investigator to make them ineligible for participation in this clinical study.

Related Conditions & MeSH terms

• Lupus Nephritis
• Nephritis

Locations

Country	Name	City	State
Korea, Republic of	Hanyang university hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Corestemchemon, Inc.	Hanyang University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events	After the completion of the CS20AT04-LN101 phase 1 trail, new adverse events, including tumor are assessed and detailed information is collected at each visit.	up to 57 months after enrollment
Primary	Incidence of abnormal results of Physical examination	Physical examination is performed at each visit. If clinically significant abnormal findings are recorded in the CRF and collected as AEs.	up to 57 months after enrollment
Primary	Percentage of abnormal Vital signs	Percentage of abnormal Blood pressure (mmHg) and Pulse rate (beat per minute)	up to 57 months after enrollment
Primary	Percentage of abnormal results of Laboratory tests	The following laboratory tests are performed at each visit; Hematology test: WBC, RBC, Hemoglobin, Hematocrit, Platelet count, WBC Diffcount, ESR; Chemistry test : Total protein, Albumin, Total bilirubin, SGOT(AST), SGPT(ALT), rGTP, Sodium, Potassium, BUN, Creatinine, Glucose, Alkaline Phosphatase, Chloride, Total cholesterol, Triglyceride, Uric Acid , CPK, LDH, CRP, Adolase; Urine analysis : Protein, Creatinine, Glucose, Urobilinogen, WBC, RBC, Urine Sediment, Creatinine, Urine albumin creatinine ratio, Urine protein creatinine ratio	up to 57 months after enrollment
Secondary	SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index-2000)	Evaluate disease activity of 9 organ systems and display it as a score. The score is weighted from 1 to 8 at each system, if descriptor is present at the time of visit or in the proceeding 10 days.; Change in SLEDAI>3 points means mild or moderate flare; Change in SLEDAI>12 points means severe flare	up to 57 months after enrollment
Secondary	BILAG 2004 (British Isles Lupus Assessment Group 2004)	The change in disease activity in the last 4 weeks compared to the previous 4 weeks is evaluated as score.	up to 57 months after enrollment
Secondary	SDI (Systemic Lupus International Collaborating Clinics/Americans College of Rheumatology (SLICC/ACR) Damage Index	Only if the damage due to the disease lasted for at least 6 months is evaluated on a scale 0-47.	up to 57 months after enrollment
Secondary	Disease activity assessed by PGA (Physician Global Assessment)	Investigator evaluated disease activity in mm using 0 to 100mm visual analogue scale (VAS). High score indicates worsening of the disease.	up to 57 months after enrollment